Molecular mechanisms contributing to the protective effect of levosimendan in liver ischemia-reperfusion injury

Mohamed A. Ibrahim, Seham A. Abdel-Gaber, Entesar F. Amin, Salwa A. Ibrahim, Rehab K. Mohammed, Aly M. Abdelrahman

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Ischemia-reperfusion injury (IRI) is an important cause of liver damage in many clinical situations. Levosimendan is a promising therapy for prevention of IRI. The present work investigated the possible contribution of nitric oxide (NO), cyclooxygenase (COX) enzymes, and adenosine triphosphate sensitive potassium channel (K-ATP) in the protective effect of levosimendan in liver IRI in rats. Rats were divided into 7 groups. Sham-operated group (negative control group); IR-nontreated group (positive control group), levosimendan-treated group (treated with levosimendan); indomethacin, nonselective COX inhibitor,+levosimendan group (cotreated with indomethacin+levosimendan); celecoxib (selective COX-2 inhibitor)+levosimendan group; L-NNA (Nitro- ω-L-arginine, nonselective NO synthase inhibitor)+levosimendan group; and glibenclamide (K-ATP blocker)+levosimendan group. Liver injury was evaluated biochemically (by serum level of alanine aminotransferase (ALT)) as well as by histopathology. Hepatic tissue content of oxidative stress markers, tumor necrosis factor-alpha (TNF-α), along with immunohistochemical expression of induced NO synthase (iNOS), endothelial NO synthase (eNOS), and caspase-3 in hepatic tissue were assayed. The study showed that levosimendan attenuated liver IRI as evidenced by a decrease in serum ALT level and confirmed by histopathology. The protective effect of levosimendan was associated with modulation of oxidative stress, TNF-α, iNOS, eNOS, and caspase-3. The hepatoprotective effect of levosimendan was partially attenuated by pretreatment by either nonselective COX inhibitor, NOS inhibitor, or K-ATP channel blocker; indicating that the hepatoprotective effect of levosimendan was attributed, at least in part to activation of COX-1, modulation of NO, and opening of K-ATP channel.

Original languageEnglish
Pages (from-to)64-73
Number of pages10
JournalEuropean Journal of Pharmacology
Volume741
DOIs
Publication statusPublished - Oct 15 2014

Fingerprint

Reperfusion Injury
Liver
Nitric Oxide Synthase
Adenosine Triphosphate
Cyclooxygenase Inhibitors
Celecoxib
Alanine Transaminase
Indomethacin
Caspase 3
simendan
Nitric Oxide
Oxidative Stress
Tumor Necrosis Factor-alpha
KATP Channels
Cyclooxygenase 1
Control Groups
Glyburide
Nitric Oxide Synthase Type III
Cyclooxygenase 2 Inhibitors
Prostaglandin-Endoperoxide Synthases

Keywords

  • levosimendan
  • Liver ischemia-reperfusion injury

ASJC Scopus subject areas

  • Pharmacology

Cite this

Molecular mechanisms contributing to the protective effect of levosimendan in liver ischemia-reperfusion injury. / Ibrahim, Mohamed A.; Abdel-Gaber, Seham A.; Amin, Entesar F.; Ibrahim, Salwa A.; Mohammed, Rehab K.; Abdelrahman, Aly M.

In: European Journal of Pharmacology, Vol. 741, 15.10.2014, p. 64-73.

Research output: Contribution to journalArticle

Ibrahim, Mohamed A. ; Abdel-Gaber, Seham A. ; Amin, Entesar F. ; Ibrahim, Salwa A. ; Mohammed, Rehab K. ; Abdelrahman, Aly M. / Molecular mechanisms contributing to the protective effect of levosimendan in liver ischemia-reperfusion injury. In: European Journal of Pharmacology. 2014 ; Vol. 741. pp. 64-73.
@article{6a3352ee1a244785b4019eff101e07ab,
title = "Molecular mechanisms contributing to the protective effect of levosimendan in liver ischemia-reperfusion injury",
abstract = "Ischemia-reperfusion injury (IRI) is an important cause of liver damage in many clinical situations. Levosimendan is a promising therapy for prevention of IRI. The present work investigated the possible contribution of nitric oxide (NO), cyclooxygenase (COX) enzymes, and adenosine triphosphate sensitive potassium channel (K-ATP) in the protective effect of levosimendan in liver IRI in rats. Rats were divided into 7 groups. Sham-operated group (negative control group); IR-nontreated group (positive control group), levosimendan-treated group (treated with levosimendan); indomethacin, nonselective COX inhibitor,+levosimendan group (cotreated with indomethacin+levosimendan); celecoxib (selective COX-2 inhibitor)+levosimendan group; L-NNA (Nitro- ω-L-arginine, nonselective NO synthase inhibitor)+levosimendan group; and glibenclamide (K-ATP blocker)+levosimendan group. Liver injury was evaluated biochemically (by serum level of alanine aminotransferase (ALT)) as well as by histopathology. Hepatic tissue content of oxidative stress markers, tumor necrosis factor-alpha (TNF-α), along with immunohistochemical expression of induced NO synthase (iNOS), endothelial NO synthase (eNOS), and caspase-3 in hepatic tissue were assayed. The study showed that levosimendan attenuated liver IRI as evidenced by a decrease in serum ALT level and confirmed by histopathology. The protective effect of levosimendan was associated with modulation of oxidative stress, TNF-α, iNOS, eNOS, and caspase-3. The hepatoprotective effect of levosimendan was partially attenuated by pretreatment by either nonselective COX inhibitor, NOS inhibitor, or K-ATP channel blocker; indicating that the hepatoprotective effect of levosimendan was attributed, at least in part to activation of COX-1, modulation of NO, and opening of K-ATP channel.",
keywords = "levosimendan, Liver ischemia-reperfusion injury",
author = "Ibrahim, {Mohamed A.} and Abdel-Gaber, {Seham A.} and Amin, {Entesar F.} and Ibrahim, {Salwa A.} and Mohammed, {Rehab K.} and Abdelrahman, {Aly M.}",
year = "2014",
month = "10",
day = "15",
doi = "10.1016/j.ejphar.2014.07.047",
language = "English",
volume = "741",
pages = "64--73",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Molecular mechanisms contributing to the protective effect of levosimendan in liver ischemia-reperfusion injury

AU - Ibrahim, Mohamed A.

AU - Abdel-Gaber, Seham A.

AU - Amin, Entesar F.

AU - Ibrahim, Salwa A.

AU - Mohammed, Rehab K.

AU - Abdelrahman, Aly M.

PY - 2014/10/15

Y1 - 2014/10/15

N2 - Ischemia-reperfusion injury (IRI) is an important cause of liver damage in many clinical situations. Levosimendan is a promising therapy for prevention of IRI. The present work investigated the possible contribution of nitric oxide (NO), cyclooxygenase (COX) enzymes, and adenosine triphosphate sensitive potassium channel (K-ATP) in the protective effect of levosimendan in liver IRI in rats. Rats were divided into 7 groups. Sham-operated group (negative control group); IR-nontreated group (positive control group), levosimendan-treated group (treated with levosimendan); indomethacin, nonselective COX inhibitor,+levosimendan group (cotreated with indomethacin+levosimendan); celecoxib (selective COX-2 inhibitor)+levosimendan group; L-NNA (Nitro- ω-L-arginine, nonselective NO synthase inhibitor)+levosimendan group; and glibenclamide (K-ATP blocker)+levosimendan group. Liver injury was evaluated biochemically (by serum level of alanine aminotransferase (ALT)) as well as by histopathology. Hepatic tissue content of oxidative stress markers, tumor necrosis factor-alpha (TNF-α), along with immunohistochemical expression of induced NO synthase (iNOS), endothelial NO synthase (eNOS), and caspase-3 in hepatic tissue were assayed. The study showed that levosimendan attenuated liver IRI as evidenced by a decrease in serum ALT level and confirmed by histopathology. The protective effect of levosimendan was associated with modulation of oxidative stress, TNF-α, iNOS, eNOS, and caspase-3. The hepatoprotective effect of levosimendan was partially attenuated by pretreatment by either nonselective COX inhibitor, NOS inhibitor, or K-ATP channel blocker; indicating that the hepatoprotective effect of levosimendan was attributed, at least in part to activation of COX-1, modulation of NO, and opening of K-ATP channel.

AB - Ischemia-reperfusion injury (IRI) is an important cause of liver damage in many clinical situations. Levosimendan is a promising therapy for prevention of IRI. The present work investigated the possible contribution of nitric oxide (NO), cyclooxygenase (COX) enzymes, and adenosine triphosphate sensitive potassium channel (K-ATP) in the protective effect of levosimendan in liver IRI in rats. Rats were divided into 7 groups. Sham-operated group (negative control group); IR-nontreated group (positive control group), levosimendan-treated group (treated with levosimendan); indomethacin, nonselective COX inhibitor,+levosimendan group (cotreated with indomethacin+levosimendan); celecoxib (selective COX-2 inhibitor)+levosimendan group; L-NNA (Nitro- ω-L-arginine, nonselective NO synthase inhibitor)+levosimendan group; and glibenclamide (K-ATP blocker)+levosimendan group. Liver injury was evaluated biochemically (by serum level of alanine aminotransferase (ALT)) as well as by histopathology. Hepatic tissue content of oxidative stress markers, tumor necrosis factor-alpha (TNF-α), along with immunohistochemical expression of induced NO synthase (iNOS), endothelial NO synthase (eNOS), and caspase-3 in hepatic tissue were assayed. The study showed that levosimendan attenuated liver IRI as evidenced by a decrease in serum ALT level and confirmed by histopathology. The protective effect of levosimendan was associated with modulation of oxidative stress, TNF-α, iNOS, eNOS, and caspase-3. The hepatoprotective effect of levosimendan was partially attenuated by pretreatment by either nonselective COX inhibitor, NOS inhibitor, or K-ATP channel blocker; indicating that the hepatoprotective effect of levosimendan was attributed, at least in part to activation of COX-1, modulation of NO, and opening of K-ATP channel.

KW - levosimendan

KW - Liver ischemia-reperfusion injury

UR - http://www.scopus.com/inward/record.url?scp=84906959520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906959520&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2014.07.047

DO - 10.1016/j.ejphar.2014.07.047

M3 - Article

VL - 741

SP - 64

EP - 73

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -